![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance Analysis of Treatment-Naïve and DAA-Experienced Genotype 1 Patients With and Without Cirrhosis Who Received Short-Duration Treatment With Sofosbuvir/Velpatasvir + GS-9857
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Ed Gane,1 Evguenia S. Svarovskaia,2 Rob Hyland,2 Luisa M. Stamm,2 Hadas Dvory-Sobol,2 Diana M. Brainard,2 Krishna Chodavarapu,2 Michael D. Miller,2 Hongmei Mo,2 Christian Schwabe1
1Auckland Clinical Studies Ltd, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, CA
AASLD: Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-Infected Patients - (11/16/15)
![AASLD1.gif](../images/121815/121815-6/AASLD1.gif)
![AASLD2.gif](../images/121815/121815-6/AASLD2.gif)
![AASLD3.gif](../images/121815/121815-6/AASLD3.gif)
![AASLD4.gif](../images/121815/121815-6/AASLD4.gif)
![AASLD5.gif](../images/121815/121815-6/AASLD5.gif)
![AASLD6.gif](../images/121815/121815-6/AASLD6.gif)
![AASLD7.gif](../images/121815/121815-6/AASLD7.gif)
![AASLD8.gif](../images/121815/121815-6/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|